Keywords: spain, new, rx, reference, price, scheme, strangle
Spain's new Rx reference price scheme "will strangle R&D and cut profits up to 25%"
Article | 22 September 2003
Spanish pharmaceutical industry observers have attacked the government's forthcoming drug reference price scheme, saying it will harm the sector by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
